Study shows Reyataz has low lipid side effects
January 07 2004 1:00 AM ET
A study of the recently approved protease inhibitor Reyataz shows that the medication is significantly less likely to boost blood-based lipid levels than similar medications, HIVandHepatitis.com reports. Previous studies have linked protease inhibitors with increases in cholesterol and triglyceride levels, which can put HIV-positive people at a higher risk for cardiac complications. A comparative study of Reyataz and Viracept among treatment-naive subjects showed that while both drugs lowered blood-based HIV viral levels, Reyataz was significantly less likely to boost LDL cholesterol and triglyceride levels. Although the long-term clinical significance of the lipid findings is still unknown, the study authors, writing in the journal AIDS, conclude that Reyataz "is a potent, safe, well-tolerated, and effective once-daily protease inhibitor with low pill burden."
- Fred Phelps Excommunicated and Near Death?
- LISTEN: Right-Wing Pundits Blast Guinness's Pullout From St. Pat's Parade
- A Brief History of Gays and the St. Patrick's Day Parade
- WATCH: Ark. High School Yearbook Refuses to Profile Out Student
- WATCH: First Gay Hug Parodies First Kiss Viral Video
- LGBT Exclusion Costs St. Paddy's Parades
- Youth School Bans Bullied Kid's My Little Pony Schoolbag 11 min 45 sec ago
- Transgender Wendy Williams Apologizes for Transphobic Panel Discussion 19 min 12 sec ago
- Television RPDR: Music Producer Lucian Piane on Pushing RuPaul & Working with Idol Contestants 25 min 20 sec ago
- Television How I Met Your Dad Adds Second Gay Character 27 min 7 sec ago
- Women WATCH: Wanda to Ellen: Look At the Lesbian Falling Off the Pole 30 min 22 sec ago
- Media LISTEN: Right-Wing Pundits Blast Guinness's Pullout From St. Pat's Parade 37 min 47 sec ago
- Travel WeHo's Most Notorious Nudie Motel Going Mainstream 1 hour 11 min ago